Cancer Type
Change My Cancer Selection

How AML Testing Advances Are Changing Patient Care

Save

Advances in testing for AML are moving swiftly, helping doctors get more comprehensive results in less time. Dr. David Sallman discusses emerging testing technologies, how faster results can speed up treatment decisions, and why more advanced testing may uncover genetic changes that traditional tests could miss.

Dr. David Sallman is an Associate Member in the Department of Malignant Hematology at Moffitt Cancer Center where he specializes in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). Learn more about Dr. Sallman.

Related Resources

Transcript

Katherine Banwell:

Dr. Sallman, what advances have been made in molecular testing for AML in recent years? And how are these advances changing patient care?

Dr. David Sallman:

Yeah. So, I think there are kind of two. So, 1.) It’s rapidly developing. I mean, really, again, I mean, even in my own group, yeah, we’re having sort of quarterly meetings on, “What do we need to change to make better?”

So, is there a gene I need to assess for or something else from that perspective? So, I’d say the two ways, one is what I mentioned a little bit, again, faster and faster technology is key. So, back in the day, some of these panels would take a month to come back and then three weeks, then four weeks. Now, there are some centers, and where I would really like most centers to be in the really coming future is, let’s say, 72 hours to have almost everything back, not this waiting 10 days, which is frustrating for patients, physicians, etc.

There are even ways to, through profiling and kind of a complex methodology, but you could actually identify even within 24 hours a very, very high pretest probability that you may have mutation A, B, or C from that perspective. So, one is faster and faster and faster, to the point if, hey, we get it next day, that would be truly amazing. I think the other is, again, different types of technology.

So, again, there are patients that through standard testing, we may miss their key mutation. But again, through things like fusion panels or optimal genome mapping and through some other technologies like that, we can now be actually much more comprehensive from that. And so, that’s the point. It’s not just a couple of basic tests, but those additional tests. Now, maybe they’re catching the 1 percent, and 99 percent of the time, we’re okay. But if you’re that 1 percent, you want to have the optimal testing.

Share On:

Facebook
Twitter
LinkedIn